| 117.79 -2.61 (-2.17%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 152.13  |
1-year : | 162.01 |
| Resists | First : | 130.25 |
Second : | 138.71 |
| Pivot price | 123.73 |
|||
| Supports | First : | 116.58 |
Second : | 96.99 |
| MAs | MA(5) : | 120.36 |
MA(20) : | 124.28 |
| MA(100) : | 134.98 |
MA(250) : | 121.33 |
|
| MACD | MACD : | -3.7 |
Signal : | -3.4 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 16.1 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 173.25 | Low : | 55.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SRPT ] has closed below the lower bollinger band by 4.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 121.28 - 121.88 | 121.88 - 122.36 |
| Low: | 114.95 - 115.75 | 115.75 - 116.4 |
| Close: | 116.67 - 117.88 | 117.88 - 118.87 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sat, 05 Oct 2024
Sei Investments Co. Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Fri, 04 Oct 2024
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics - Benzinga
Fri, 04 Oct 2024
Clearbridge Investments LLC Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thu, 03 Oct 2024
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Hsbc Holdings PLC - MarketBeat
Mon, 30 Sep 2024
Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Yahoo Finance
Thu, 26 Sep 2024
The Play On Sarepta Therapeutics (NASDAQ:SRPT) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 95.4 (%) |
| Shares Short | 6,150 (K) |
| Shares Short P.Month | 6,730 (K) |
| EPS | 0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.3 |
| Profit Margin | 3.1 % |
| Operating Margin | -0.2 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | 5.1 % |
| Qtrly Rev. Growth | 38.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 15.72 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -397 (M) |
| Levered Free Cash Flow | -408 (M) |
| PE Ratio | 157.05 |
| PEG Ratio | 0.8 |
| Price to Book value | 10.42 |
| Price to Sales | 7.48 |
| Price to Cash Flow | -28.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|